Metformin to target leukemia-related mutation during remission
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if metformin can reduce a specific mutation (DNMT3A R882) in people with acute leukemia who are in remission. The goal is to see if it helps prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia and are currently in remission.
- You have a specific mutation called DNMT3A R882, with a level of at least 5%.
- You are 14 years or older.
- Your liver, kidney, and heart function are within safe limits.
- You are not taking other diabetes medications.
- You are not allergic to metformin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This Phase 2 study tests whether metformin can lower the risk of leukemia developing in people with low-risk myelodysplastic syndrome (LR-MDS) or CCUS. You may be considered if your blood counts have stayed low and other causes have been ruled out.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
Hear when a new DNMT3A Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.